Septerna, Inc. SEPN
Septerna, Inc. (Nasdaq: SEPN) is a drug developer. Its lead program, SEP-479, is in Phase 1 for Not specified in reviewed text. Its next catalyst on record is SEP-479: SEP-479 Phase 1 SAD/MAD data anticipated in Q1 2027. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SEP-479 — SEP-479 Phase 1 SAD/MAD data anticipated in Q1 2027. (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SEP-479 | Phase 1 SAD/MAD | small molecule | Phase 1 |
| SEP-631 | Chronic spontaneous urticaria | small molecule | Pre-clinical |
Recent results and decisions
- Apr 13, 2026positive Corporate deck summarizes Phase 1 SEP-631 results: full inhibition of icatibant-induced wheals at lowest dose 10 mg QD, once-daily dosing (half-life ~24 hrs), all AEs mild or moderate.
SEP-631 completely inhibited icatibant 10 μg/mL-induced wheals at 10 mg QD, the lowest dose evaluated
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.